|
|
|
| Efficacy of Pyrrotinib Combined with Chemotherapy in the Treatment of HER2 Positive Advanced Breast Cancer |
| ZHAO Xiao-yu, SONG Zhong-hua, QU Xiang-hui |
| Department of General Medicine, Shandong Provincial Third Hospital Jinan,Jinan Shandong 250031 |
|
|
|
|
Abstract 【Objective】To explore the efficacy and survival status of pyrrotinib combined with chemotherapy in the treatment of human epidermal growth factor receptor 2 (HER2) positive advanced breast cancer. 【Methods】A total of 72 patients with HER2 positive advanced breast cancer admitted to our hospital was randomly divided into observation group and control group, 36 cases in each group. The control group was treated with routine chemotherapy, and the observation group was treated with pyrrotinib combined with chemotherapy. The use of chemotherapy drugs, short-term clinical efficacy, adverse reactions and survival of the two groups were compared.【Results】The clinical control rate in the observation group was 69.44% (25/36), which was significantly higher than 47.22% (17/36) in the control group (P<0.05). There was no significant difference in the incidence of adverse reactions such as nausea, vomiting, hair loss and fatigue between the observation group and the control group (P>0.05). After 6 months of follow-up, the survival rates of the control group and the observation group were 80.00% and 88.24% respectively. There was no significant difference in the survival curve between the two groups (P>0.05). 【Conclusion】Pyrrotinib combined with chemotherapy in the treatment of HER2 positive advanced breast cancer patients can improve the clinical control rate and is safe and reliable. However, the survival rate of patients with follow-up of 6 months after operation is not significantly improved.
|
|
Received: 28 June 2021
|
|
|
|
|
|
[1] RUGO H S, FINN R S, DIéRAS V, et al. Palbociclib plus letrozole as first-line therapy in estrogen receptor-positive/human epidermal growth factor receptor 2-negative advanced breast cancer with extended follow-up[J].Breast Cancer Res Treat,2019, 174(3):719-729.
[2] 颜廷俊.血清肿瘤标记物联合动态检测在乳腺癌诊疗中的应用[J].实用临床医药杂志, 2019, 23(11):42-45.
[3] 宋国红, 肖宇, 张如艳, 等. 吡咯替尼治疗HER2阳性转移性乳腺癌的疗效及安全性[J].北京大学学报(医学版), 2020, 52(2):254-260.
[4] MA F, OUYANG Q, LI W, et al. Pyrotinib or lapatinib combined with capecitabine in her2-positive metastatic breast cancer with prior taxanes, anthracyclines, and/or trastuzumab: a randomized, phase ii study [J].J Clin Oncol,2019, 37(29):2610-2619.
[5] XUHONG J C, QI X W, ZHANG Y, et al. Mechanism, safety and efficacy of three tyrosine kinase inhibitors lapatinib, neratinib and pyrotinib in HER2-positive breast cancer [J].Am J Cancer Res,2019, 9(10):2103-2119.
[6] 江泽飞, 邵志敏, 徐兵河. 人表皮生长因子受体2阳性乳腺癌临床诊疗专家共识[J].中华肿瘤杂志, 2010, 45(2):158-160.
[7] EISENHAUER E A. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1) [J].Eur J Cancer,2009, 45(2):228-247.
[8] MODI S, SAURA C, YAMASHITA T, et al. Trastuzumab deruxtecan in previously treated her2-positive breast cancer [J].N Engl J Med,2020, 382(7):610-621.
[9] RIMAWI M. First-Line trastuzumab plus an aromatase inhibitor, with or without pertuzumab, in human epidermal growth factor receptor 2-positive and hormone receptor-positive metastatic or locally advanced breast cancer (pertain): a randomized, open-label phase ii trial [J].J Clin Oncol,2018, 36(28):2826-2835.
[10] 关格格, 孙秋实, 王玲, 等. 吡咯替尼治疗HER-2阳性晚期乳腺癌的近期疗效及安全性[J].国际肿瘤学杂志, 2019, 46(9):570-573.
[11] TELLI M L, GRADISHAR W J, WARD J H. NCCN guidelines updates: breast cancer [J].J Natl Compr Canc Netw,2019, 17(5):552-555.
[12] 国家肿瘤质控中心乳腺癌专家委员会, 中国抗癌协会乳腺癌专业委员会, 中国抗癌协会肿瘤药物临床研究专业委员会, 等. 中国晚期乳腺癌规范诊疗指南(2020版)[J].中华肿瘤杂志, 2020, 42(10):781-797. |
|
|
|
2022, Vol. 39 
